Written by
Mustafa Çelik
Mustafa Çelik Liv Hospital Content Team
Medically reviewed by

Related Doctors

Assoc. Prof. MD. Evrim Duman Liv Hospital Ulus Assoc. Prof. MD. Evrim Duman Radiation Oncology Asst. Prof. MD. Meltem Topalgökçeli Selam Liv Hospital Ulus Asst. Prof. MD. Meltem Topalgökçeli Selam Medical Oncology Prof. MD. Duygu Derin Liv Hospital Ulus Prof. MD. Duygu Derin Medical Oncology Prof. MD. Emre Merdan Fayda Liv Hospital Ulus Prof. MD. Emre Merdan Fayda Radiation Oncology Prof. MD. Meral Günaldı Liv Hospital Ulus Prof. MD. Meral Günaldı Medical Oncology Assoc. Prof. MD. Murat Ayhan Liv Hospital Vadistanbul Assoc. Prof. MD. Murat Ayhan Medical Oncology Prof. MD.  Itır Şirinoğlu Demiriz Liv Hospital Vadistanbul Prof. MD. Itır Şirinoğlu Demiriz Hematology Prof. MD. Tülin Tıraje Celkan Liv Hospital Vadistanbul Prof. MD. Tülin Tıraje Celkan Pediatric Hematology and Oncology Assoc. Prof. MD. Erkan Kayıkçıoğlu Liv Hospital Bahçeşehir Assoc. Prof. MD. Erkan Kayıkçıoğlu Medical Oncology Assoc. Prof. MD. Mine Dağgez Liv Hospital Bahçeşehir Assoc. Prof. MD. Mine Dağgez Gynecological Oncology Assoc. Prof. MD. Ozan Balakan Liv Hospital Bahçeşehir Assoc. Prof. MD. Ozan Balakan Medical Oncology MD. Taylan Bükülmez Liv Hospital Bahçeşehir MD. Taylan Bükülmez Radiation Oncology Op. MD. Alp Koray Kinter Liv Hospital Bahçeşehir Op. MD. Alp Koray Kinter Gynecological Oncology Prof. MD. Nuri Faruk Aykan Liv Hospital Bahçeşehir Prof. MD. Nuri Faruk Aykan Medical Oncology Prof. MD. Yasemin Altuner Torun Liv Hospital Bahçeşehir Prof. MD. Yasemin Altuner Torun Pediatric Hematology and Oncology Spec. MD. Özlem Doğan Liv Hospital Bahçeşehir Spec. MD. Özlem Doğan Medical Oncology Assoc. Prof. MD. Emir Çelik Liv Hospital Topkapı Assoc. Prof. MD. Emir Çelik Medical Oncology Assoc. Prof. MD. Muhammed Mustafa Atcı Liv Hospital Topkapı Assoc. Prof. MD. Muhammed Mustafa Atcı Medical Oncology Prof. MD. İrfan Çiçin Liv Hospital Topkapı Prof. MD. İrfan Çiçin Medical Oncology Assoc. Prof. MD.  Ramazan Öcal Liv Hospital Ankara Assoc. Prof. MD. Ramazan Öcal Hematology Assoc. Prof. MD. Nazlı Topfedaisi Özkan Liv Hospital Ankara Assoc. Prof. MD. Nazlı Topfedaisi Özkan Gynecological Oncology Prof. MD. Fikret Arpacı Liv Hospital Ankara Prof. MD. Fikret Arpacı Medical Oncology Prof. MD. Gökhan Erdem Liv Hospital Ankara Prof. MD. Gökhan Erdem Medical Oncology Prof. MD. Meral Beksaç Liv Hospital Ankara Prof. MD. Meral Beksaç Hematology Prof. MD. Oral Nevruz Liv Hospital Ankara Prof. MD. Oral Nevruz Hematology Prof. MD. Saadettin Kılıçkap Liv Hospital Ankara Prof. MD. Saadettin Kılıçkap Medical Oncology Prof. MD. Sadık Muallaoğlu Liv Hospital Ankara Prof. MD. Sadık Muallaoğlu Medical Oncology Spec. MD. Ender Kalacı Liv Hospital Ankara Spec. MD. Ender Kalacı Medical Oncology Assoc. Prof. MD. Fadime Ersoy Dursun Liv Hospital Gaziantep Assoc. Prof. MD. Fadime Ersoy Dursun Hematology Prof. MD. Fatih Teker Liv Hospital Gaziantep Prof. MD. Fatih Teker Medical Oncology Spec. MD. ELXAN MEMMEDOV Liv Bona Dea Hospital Bakü Spec. MD. ELXAN MEMMEDOV Medical Oncology Spec. MD. Ceyda Aslan Spec. MD. Ceyda Aslan Hematology Spec. MD. Elkhan Mammadov Spec. MD. Elkhan Mammadov Medical Oncology Spec. MD. Elmir İsrafilov Spec. MD. Elmir İsrafilov Hematology Spec. MD. Minure Abışova Eliyeva Spec. MD. Minure Abışova Eliyeva Hematology Spec. MD. Natavan Azizova Spec. MD. Natavan Azizova Medical Oncology Prof. MD. Mehmet Hilmi Doğu Liv Hospital Ulus + Liv Hospital Bahçeşehir Prof. MD. Mehmet Hilmi Doğu Hematology
...
Views
Read Time
...
views
Read Time
SEP 15191 image 1 LIV Hospital
Why Have A Mastectomy For Dcis? Scary Risks 4

Ductal carcinoma in situ (DCIS) is a type of breast cancer that doesn’t spread outside the milk ducts. It’s not deadly if caught early. But, it can turn into a more serious cancer if not treated right.

Knowing the risk of DCIS recurrence is key for both patients and doctors. It helps them make better choices for follow-up and treatment.

Research shows that DCIS recurrence usually happens 5 to 10 years after treatment. The chance of it coming back depends on several things. These include the DCIS grade, how much cancer is left after surgery, and if extra treatments like radiation are used.

At Liv Hospital, we offer detailed care. Our approach includes proven methods and team-based treatment plans. We aim to lower the risk of recurrence.

Key Takeaways

  • DCIS recurrence typically occurs within 5 to 10 years after treatment.
  • The risk of recurrence depends on factors like DCIS grade and margin status.
  • Liv Hospital offers comprehensive care to manage DCIS recurrence risk.
  • Additional treatments like radiation therapy can impact recurrence risk.
  • Understanding DCIS recurrence risk is key for informed treatment choices.

Understanding DCIS: A Precancerous Condition

SEP 15191 image 2 LIV Hospital
Why Have A Mastectomy For Dcis? Scary Risks 5

Understanding DCIS is key for those diagnosed with this condition. It can turn into invasive breast cancer if not treated. DCIS has abnormal cells in the milk ducts but doesn’t spread to other tissues.

What is Ductal Carcinoma in Situ?

Ductal carcinoma in situ (DCIS) is a type of non-invasive breast cancer. It means the cells are stuck in the milk ducts. It’s seen as a warning sign because it might become invasive if not treated right.

It’s usually found during mammograms. More people are getting diagnosed because of regular screenings.

How DCIS Differs from Invasive Breast Cancer

DCIS and invasive breast cancer are different. DCIS cells stay in the ducts and don’t spread. Invasive cancer, on the other hand, breaks out of the ducts and grows in the breast tissue.

Knowing this helps doctors choose the best treatment.

Prevalence and Detection Methods

DCIS is the most common breast cancer found by mammograms. It makes up about 20% of all breast cancers found this way. Catching it early with mammograms is key to managing it well.

  • DCIS is often asymptomatic and detected through mammography.
  • The risk of DCIS becoming invasive can be significantly reduced with proper treatment.
  • ER-positive DCIS may benefit from hormonal therapy.

By understanding DCIS, patients can make better choices about their treatment. This helps lower the chance of it coming back.

Typical Recurrence Timeframes for DCIS

SEP 15191 image 3 LIV Hospital
Why Have A Mastectomy For Dcis? Scary Risks 6

Knowing when DCIS might come back is key for both patients and doctors. DCIS can recur at different times after treatment. Knowing these times helps in managing the condition better.

Early Recurrence (Within First 5 Years)

The first five years after treatment are very important. Most recurrences happen during this time. Studies show that the DCIS recurrence rate is higher in the first years, mainly for higher-grade DCIS. For example, grade 3 DCIS has a higher risk of coming back compared to lower grades.

Later Recurrence Patterns (5-10 Years)

Even though the risk is highest in the first five years, DCIS can come back between 5 to 10 years after treatment. It’s important to have regular check-ups during this time to catch any recurrence early. The dcis grade 2 recurrence rate and dcis grade 3 recurrence rate are important to consider during this period.

Long-term Recurrence Risk (Beyond 10 Years)

DCIS can also come back more than 10 years after treatment, though it’s less common. Long-term monitoring is needed to manage this risk. Knowing how fast DCIS progresses helps in planning long-term care and follow-up strategies.

By understanding these typical recurrence timeframes, patients and healthcare providers can create a personalized follow-up plan. This can help reduce the risk of recurrence and improve outcomes.

Statistical Overview of DCIS Recurrence Rates

Looking at DCIS recurrence rates is key to understanding the risk. This knowledge helps both patients and doctors make better choices about treatment and follow-up care.

Overall Recurrence Percentages

Research shows that DCIS recurrence rates vary. A meta-analysis found a 20% recurrence rate after just lumpectomy. Several factors, like the surgery margin and adjuvant treatments, can affect this rate.

A study in the Journal of Clinical Oncology found a big difference in recurrence rates. Patients who had lumpectomy and then radiation therapy had a much lower 10-year recurrence rate than those who only had lumpectomy. This shows how important adjuvant therapy is in lowering the risk of recurrence.

Recurrence Rates Based on Treatment Approach

The treatment for DCIS greatly affects recurrence rates. Options include lumpectomy alone, lumpectomy with radiation, and sometimes mastectomy.

Treatment Approach

Recurrence Rate

Lumpectomy Alone

Approximately 20%

Lumpectomy with Radiation Therapy

Significantly lower than lumpectomy alone

Mastectomy

Lowest recurrence rate

Invasive vs. Non-invasive Recurrence Statistics

Recurrences can be invasive or non-invasive (DCIS). Knowing the type of recurrence is important for patient care.

“The risk of invasive recurrence is a significant concern for DCIS patients, and the choice of initial treatment can substantially impact this risk.”

— Expert Opinion

Research shows that about half of recurrences are invasive, and the other half is non-invasive (DCIS). High-grade DCIS and close or positive margins after surgery increase the risk of invasive recurrence.

Understanding these statistics helps doctors advise patients on treatment options and the risks of recurrence.

Key Risk Factors That Influence DCIS Recurrence

Several factors can affect the risk of DCIS recurrence. These include the patient’s age and the characteristics of the disease. Knowing these factors helps doctors create better treatment plans and lower the chance of recurrence.

Age-Related Risk Factors

Younger patients face a higher risk of DCIS coming back. Research shows women under 40 are more likely to see recurrence than older women. This is because younger patients often have more aggressive tumors.

Pathological Features Affecting Recurrence

The type and how much of the DCIS is found during surgery are key. High-grade DCIS and margins that are close or positive increase the risk of recurrence.

Pathological Feature

Risk Level

Description

High Nuclear Grade

High

Increased risk of recurrence due to aggressive tumor biology

Close or Positive Margins

High

Increased risk of recurrence due to residual disease

ER-Positive DCIS

Variable

May benefit from hormonal therapy, reducing recurrence risk

Detection Method as a Predictor

How DCIS is found also matters. DCIS found by physical exam is more likely to come back than that found by mammography. This is because tumors found by symptoms might be bigger or more aggressive.

Understanding these risk factors helps doctors make treatment plans that are more effective. This can help lower the risk of DCIS coming back.

The Role of Nuclear Grade in DCIS Recurrence

Knowing the nuclear grade of ductal carcinoma in situ (DCIS) is key to understanding recurrence risk. The nuclear grade shows how much the tumor cells look like normal cells. It helps figure out how aggressive the disease is.

Low-Grade DCIS Recurrence Patterns

Low-grade DCIS has cells that look almost like normal breast cells. Research shows it has a lower risk of coming back compared to higher grades. For example, the dcis grade 2 recurrence rate is higher than grade 1, showing a rise in risk with higher grades.

Intermediate-Grade DCIS Outcomes

Grade 2 DCIS falls in the middle in terms of cell abnormality. The recurrence rate for grade 2 DCIS is being studied. It seems to be between low-grade and high-grade DCIS. Knowing the dcis grade 2 recurrence rate helps in making treatment plans.

High-Grade DCIS and Elevated Recurrence Risk

High-grade DCIS has a high nuclear grade and a higher risk of coming back. The cells in high-grade DCIS are very abnormal and more likely to turn into invasive cancer. The dcis grade 3 recurrence rate is much higher, showing the need for aggressive treatment and close monitoring.

Nuclear Grade

Recurrence Risk

Typical Treatment Approach

Low-Grade

Lower

Lumpectomy, possibly without radiation

Intermediate-Grade

Moderate

Lumpectomy with radiation therapy

High-Grade

Higher

Mastectomy or lumpectomy with radiation, considering additional therapies

The nuclear grade is a key factor in DCIS recurrence risk. Understanding its implications helps healthcare providers create better treatment plans. These plans are tailored to each patient’s risk level.

Surgical Margins and Their Impact on Recurrence

Understanding how surgical margins affect DCIS recurrence is key for good treatment plans. The status of the margins after DCIS surgery is very important. It helps figure out the risk of recurrence.

Positive Margins and Recurrence Correlation

Positive surgical margins mean a higher risk of DCIS coming back. If cancer cells are found at the edge of the removed tissue, it means some cancer might have been left behind. This increases the chance of recurrence.

Close Margins: Defining the Threshold

Close margins mean cancer cells are near but not at the edge of the removed tissue. The exact meaning of “close” can vary. But generally, it means the cancer cells are just a few millimeters from the margin. The risk of recurrence is higher with close margins than with negative margins.

Negative Margins and Reduced Recurrence Risk

Negative margins mean no cancer cells are found at the edge of the removed tissue. This is linked to a lower risk of recurrence. Getting negative margins is a main goal of DCIS surgery. It greatly lowers the chance of the cancer coming back.

Talking to your healthcare provider about your surgical margins is important. They can explain what it means for your treatment plan and follow-up care.

Key Considerations for Surgical Margins:

  • The presence of cancer cells at or near the surgical margin increases recurrence risk.
  • Achieving negative margins is key for lowering the risk of DCIS recurrence.
  • The definition of “close margins” can vary, but it generally refers to cancer cells being within a few millimeters of the margin.

Why Have a Mastectomy for DCIS? Weighing Treatment Options

Choosing a mastectomy for DCIS depends on several things. These include the chance of cancer coming back and what the patient prefers. When someone finds out they have ductal carcinoma in situ (DCIS), they must think about the good and bad of each surgery option.

Lumpectomy vs. Mastectomy Recurrence Outcomes

Research shows both lumpectomy and mastectomy work well for DCIS. But, the chance of cancer coming back is different for each. A lumpectomy might have a higher risk of recurrence than a mastectomy, which takes out the whole breast.

Treatment

Recurrence Rate

Description

Lumpectomy

10-15%

Removal of DCIS with a margin of healthy tissue

Mastectomy

1-2%

Removal of the entire breast

When Mastectomy May Be Recommended

Mastectomy might be suggested for those with high-grade DCIS or if lumpectomy margins are close or positive. It’s also considered for those with a family history of breast cancer or genetic mutations.

Patient Decision Factors Beyond Recurrence Risk

While thinking about recurrence risk is key, there’s more to consider. Patients should think about how each surgery will look, the need for radiation after lumpectomy, and their own wishes about keeping their breast.

In the end, choosing between lumpectomy and mastectomy for DCIS should be a thoughtful decision. It should be made after looking at personal risks and talking to a healthcare provider.

Radiation Therapy’s Effect on DCIS Recurrence Rates

When looking at DCIS treatment, knowing how radiation therapy affects recurrence rates is key. Radiation is often used after lumpectomy to lower the chance of DCIS coming back.

Lumpectomy Alone vs. Lumpectomy with Radiation

Research shows that adding radiation to lumpectomy cuts DCIS recurrence rates in half. A lumpectomy alone might not get rid of all cancer cells, leading to recurrence.

Studies say radiation after lumpectomy can cut recurrence risk by up to 50%. This shows how vital radiation is in treating DCIS.

“The addition of radiation therapy to lumpectomy has been shown to significantly reduce the risk of DCIS recurrence, providing patients with a more effective treatment option.”

Radiation Therapy Protocols for DCIS

Radiation therapy plans for DCIS depend on several things, like DCIS grade and margin status. Radiation is given over weeks, with doses split to lessen side effects.

Treatment

Recurrence Rate

Benefit

Lumpectomy Alone

Higher

Less Effective

Lumpectomy with Radiation

Lower

More Effective

Identifying Patients Who Benefit Most from Radiation

Not every DCIS patient needs radiation therapy. Age, DCIS grade, and margin status are key in deciding if radiation is needed. Those with high-grade DCIS or close margins might get more benefit from radiation.

Understanding radiation therapy’s benefits and protocols helps doctors choose the best treatment for DCIS patients.

Hormonal Therapy for Reducing DCIS Recurrence

For those with ER-positive ductal carcinoma in situ (DCIS), hormonal therapy is a good choice. It helps lower the chance of the disease coming back. This is because ER-positive DCIS has estrogen receptors, which hormonal treatments can target.

ER-Positive DCIS and Hormonal Interventions

Hormonal therapy works well for ER-positive DCIS patients. It cuts down estrogen levels or blocks its effects. This makes it less likely for the disease to come back. Tamoxifen and aromatase inhibitors are two main types of hormonal therapy.

Effectiveness of Tamoxifen and Aromatase Inhibitors

Research shows Tamoxifen can greatly lower DCIS recurrence risk in ER-positive patients. Aromatase inhibitors also work well, mainly for postmenopausal women. Here’s a comparison of their effectiveness:

Therapy

Recurrence Reduction

Target Population

Tamoxifen

Up to 50%

Pre- and Postmenopausal Women

Aromatase Inhibitors

Up to 60%

Postmenopausal Women

Balancing Benefits Against Side Effects

Hormonal therapy is effective but comes with side effects. These can include hot flashes, osteoporosis, and a higher risk of blood clots. It’s important to consider these when choosing a treatment plan.

Follow-Up Protocols After DCIS Treatment

After DCIS treatment, a good follow-up plan is key. It helps catch any signs of the disease coming back early. This way, doctors can act fast if something changes in the breast tissue.

Recommended Surveillance Schedule

It’s best to have regular mammograms, every 6 to 12 months for a few years after treatment. The exact schedule might change based on your risk and treatment details.

Imaging Modalities for Monitoring

Mammograms are the main tool for checking up. Sometimes, breast MRI is suggested for those at higher risk. A study shows MRI can find more problems in high-risk cases.

Clinical Examinations and Their Importance

Don’t forget about regular check-ups by a healthcare provider. These exams can spot issues that imaging might miss. Experts say, “Finding problems early is the best way to manage DCIS recurrence.”

Following a detailed follow-up plan can greatly increase your chances of catching any recurrence early. This makes it easier to treat.

Liv Hospital’s Approach to DCIS Management

Liv Hospital is known for its focus on evidence-based treatments for DCIS. We offer a detailed care plan that meets each patient’s unique needs.

Multidisciplinary Treatment Planning

Our team at Liv Hospital believes in a team effort for DCIS management. Surgeons, oncologists, radiologists, and other experts work together. They create a treatment plan that’s just right for each patient.

Evidence-Based Protocols for Optimal Outcomes

We follow the latest evidence-based protocols for our patients. This means using the most advanced diagnostic tools and treatments. These are chosen based on each patient’s DCIS characteristics.

Personalized Risk Assessment and Treatment

We also do a detailed risk assessment for each patient. This helps us figure out if they need more aggressive treatment. We use both clinical checks and advanced tools to decide the best treatment.

Key Components

Description

Benefits

Multidisciplinary Team

Collaboration among surgeons, oncologists, and radiologists

Comprehensive care and personalized treatment plans

Evidence-Based Protocols

Use of latest research and guidelines

Optimal treatment outcomes and reduced recurrence risk

Personalized Risk Assessment

Thorough evaluation of patient risk factors

Tailored treatment strategies for improved outcomes

Conclusion: Managing DCIS Recurrence Risk Effectively

Managing DCIS recurrence risk is key for those treated for this precancerous condition. Knowing the risk factors and using proven methods can lower recurrence chances. At Liv Hospital, we focus on quality care that helps patients manage their condition well.

Following up closely and getting the right treatment are vital. Our team creates personalized plans for each patient. We use the latest medical treatments and support services to guide patients through their care.

Long-term follow-up care is essential for managing DCIS recurrence risk. Our patients get a detailed surveillance plan, advanced imaging, and regular check-ups. This proactive approach leads to better outcomes and less worry for patients.

FAQ

What is DCIS, and how does it differ from invasive breast cancer?

DCIS, or ductal carcinoma in situ, is a non-invasive breast cancer. It means abnormal cells are stuck in the milk ducts. Unlike invasive cancer, DCIS hasn’t spread to the rest of the breast.

How is DCIS typically detected?

DCIS is often found through mammograms. These tests are more common now thanks to screening programs.

What are the risk factors for DCIS recurrence?

Several things can increase the chance of DCIS coming back. These include the type of DCIS, how much tissue was removed, and if extra treatments like radiation were used.

How quickly can DCIS recur after treatment?

DCIS can come back anytime, but most often within 5 to 10 years after treatment.

Does the grade of DCIS affect the risk of recurrence?

Yes, the grade of DCIS matters. Higher grades are more likely to come back.

What is the impact of surgical margins on DCIS recurrence?

If the margins are close or positive after surgery, the risk of recurrence goes up. But, if the margins are clear, the risk goes down.

How does radiation therapy affect DCIS recurrence rates?

Radiation therapy after a lumpectomy can lower the risk of DCIS coming back. It’s more effective than just a lumpectomy alone.

Is hormonal therapy effective in reducing DCIS recurrence?

For patients with ER-positive DCIS, hormonal therapy can help. It includes tamoxifen and aromatase inhibitors to lower the risk of recurrence.

What is the recommended follow-up protocol after DCIS treatment?

After DCIS treatment, regular check-ups are key. They include imaging tests and doctor visits to catch any signs of recurrence early.

Will DCIS become invasive if left untreated?

Untreated DCIS can turn into invasive breast cancer. But, with the right treatment, the risk is much lower.

How does Liv Hospital approach DCIS management?

Liv Hospital uses a team of experts and follows proven treatment plans. They also assess each patient’s risk to ensure the best care.

Can DCIS recur after mastectomy?

Mastectomy greatly lowers the risk of recurrence. But, it’s not a complete guarantee. The risk is very low, though.

What are the benefits of lumpectomy followed by radiation therapy for DCIS?

This approach can significantly lower the risk of DCIS coming back. It’s more effective than just a lumpectomy alone.

References

PubMed: https://pubmed.ncbi.nlm.nih.gov/10091735/

i

Medical Disclaimer

The content on this page is for informational purposes only and is not a substitute for professional medical advice, diagnosis or treatment. Always consult a qualified healthcare provider regarding any medical conditions.

Book a Free Certified Online
Doctor Consultation

Clinics/branches
GDPR

We're Here to Help.
Get in Touch

Send us all your questions or requests, and our
expert team will assist you.

Our Doctors

Assoc. Prof. MD. Evrim Duman Radiation Oncology

Assoc. Prof. MD. Evrim Duman

Liv Hospital Ulus
Asst. Prof. MD. Meltem Topalgökçeli Selam Medical Oncology

Asst. Prof. MD. Meltem Topalgökçeli Selam

Liv Hospital Ulus
Prof. MD. Duygu Derin Medical Oncology

Prof. MD. Duygu Derin

Liv Hospital Ulus
Prof. MD. Emre Merdan Fayda Radiation Oncology

Prof. MD. Emre Merdan Fayda

Liv Hospital Ulus
Prof. MD. Mehmet Hilmi Doğu Hematology

Prof. MD. Mehmet Hilmi Doğu

Liv Hospital Ulus
Liv Hospital Bahçeşehir
Prof. MD. Meral Günaldı Medical Oncology

Prof. MD. Meral Günaldı

Liv Hospital Ulus
Assoc. Prof. MD. Murat Ayhan Medical Oncology

Assoc. Prof. MD. Murat Ayhan

Liv Hospital Vadistanbul
Prof. MD.  Itır Şirinoğlu Demiriz Hematology

Prof. MD. Itır Şirinoğlu Demiriz

Liv Hospital Vadistanbul
Prof. MD. Tülin Tıraje Celkan Pediatric Hematology and Oncology

Prof. MD. Tülin Tıraje Celkan

Liv Hospital Vadistanbul
Assoc. Prof. MD. Erkan Kayıkçıoğlu Medical Oncology

Assoc. Prof. MD. Erkan Kayıkçıoğlu

Liv Hospital Bahçeşehir
Assoc. Prof. MD. Mine Dağgez Gynecological Oncology

Assoc. Prof. MD. Mine Dağgez

Liv Hospital Bahçeşehir
Assoc. Prof. MD. Ozan Balakan Medical Oncology

Assoc. Prof. MD. Ozan Balakan

Liv Hospital Bahçeşehir
MD. Taylan Bükülmez Radiation Oncology

MD. Taylan Bükülmez

Liv Hospital Bahçeşehir
Op. MD. Alp Koray Kinter Gynecological Oncology

Op. MD. Alp Koray Kinter

Liv Hospital Bahçeşehir
Prof. MD. Nuri Faruk Aykan Medical Oncology

Prof. MD. Nuri Faruk Aykan

Liv Hospital Bahçeşehir
Prof. MD. Yasemin Altuner Torun Pediatric Hematology and Oncology

Prof. MD. Yasemin Altuner Torun

Liv Hospital Bahçeşehir
Spec. MD. Özlem Doğan Medical Oncology

Spec. MD. Özlem Doğan

Liv Hospital Bahçeşehir
Assoc. Prof. MD. Emir Çelik Medical Oncology

Assoc. Prof. MD. Emir Çelik

Liv Hospital Topkapı
Assoc. Prof. MD. Muhammed Mustafa Atcı Medical Oncology

Assoc. Prof. MD. Muhammed Mustafa Atcı

Liv Hospital Topkapı
Prof. MD. İrfan Çiçin Medical Oncology

Prof. MD. İrfan Çiçin

Liv Hospital Topkapı
Assoc. Prof. MD.  Ramazan Öcal Hematology

Assoc. Prof. MD. Ramazan Öcal

Liv Hospital Ankara
Assoc. Prof. MD. Nazlı Topfedaisi Özkan Gynecological Oncology

Assoc. Prof. MD. Nazlı Topfedaisi Özkan

Liv Hospital Ankara
Prof. MD. Fikret Arpacı Medical Oncology

Prof. MD. Fikret Arpacı

Liv Hospital Ankara
Prof. MD. Gökhan Erdem Medical Oncology

Prof. MD. Gökhan Erdem

Liv Hospital Ankara
Prof. MD. Meral Beksaç Hematology

Prof. MD. Meral Beksaç

Liv Hospital Ankara
Prof. MD. Oral Nevruz Hematology

Prof. MD. Oral Nevruz

Liv Hospital Ankara
Prof. MD. Saadettin Kılıçkap Medical Oncology

Prof. MD. Saadettin Kılıçkap

Liv Hospital Ankara
Prof. MD. Sadık Muallaoğlu Medical Oncology

Prof. MD. Sadık Muallaoğlu

Liv Hospital Ankara
Spec. MD. Ender Kalacı Medical Oncology

Spec. MD. Ender Kalacı

Liv Hospital Ankara
Assoc. Prof. MD. Fadime Ersoy Dursun Hematology

Assoc. Prof. MD. Fadime Ersoy Dursun

Liv Hospital Gaziantep
Prof. MD. Fatih Teker Medical Oncology

Prof. MD. Fatih Teker

Liv Hospital Gaziantep
Spec. MD. ELXAN MEMMEDOV Medical Oncology

Spec. MD. ELXAN MEMMEDOV

Liv Bona Dea Hospital Bakü
Spec. MD. Ceyda Aslan Hematology

Spec. MD. Ceyda Aslan

Spec. MD. Elkhan Mammadov Medical Oncology

Spec. MD. Elkhan Mammadov

Spec. MD. Elmir İsrafilov Hematology

Spec. MD. Elmir İsrafilov

Spec. MD. Minure Abışova Eliyeva Hematology

Spec. MD. Minure Abışova Eliyeva

Spec. MD. Natavan Azizova Medical Oncology

Spec. MD. Natavan Azizova

Need Help? Chat with our medical team

Let's Talk on WhatsApp

📌

Get instant answers from our medical team. No forms, no waiting — just tap below to start chatting now.

or call us at +90 530 174 42 01